Spruce Biosciences (SPRB) Research & Development (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Research & Development of $7.6 million for Q1 2026, down 30.1% year-over-year from $10.8 million in Q1 2025, and up 84.58% quarter-over-quarter from $4.1 million in Q4 2025.
Spruce Biosciences (SPRB) Research & Development (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Research & Development for 8 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development fell 30.1% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $16.3 million (down 65.36% YoY), while the FY2025 annual figure was $19.5 million, down 57.94% from the prior year.
- Research & Development rose to $7.6 million in Q1 2026 per SPRB's latest filing, from $4.1 million in the prior quarter.
- Across five years, Research & Development topped out at $21.5 million in Q4 2024 and bottomed at -$430000.0 in Q2 2025.
- Historically, Research & Development has averaged $9.3 million across 5 years, with a median of $8.8 million in 2022.
- Annual changes were most pronounced in 2024 — Research & Development soared 93.31% — and 2025, when it tumbled 105.32%.
- Spruce Biosciences' Research & Development stood at $8.8 million in 2022, then advanced by 25.58% to $11.1 million in 2023, then jumped by 93.31% to $21.5 million in 2024, then slumped by 80.87% to $4.1 million in 2025, then surged by 84.58% to $7.6 million in 2026.
- Business Quant data shows SPRB's Research & Development at $7.6 million in Q1 2026, $4.1 million in Q4 2025, and $5.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Spruce Biosciences | 127.07 Mn | 127.07 Mn | - | 12.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.16 Mn |
| Mar 31, 2026 | 7.58 Mn |
| Dec 31, 2025 | 4.10 Mn |
| Sep 30, 2025 | 5.01 Mn |
| Jun 30, 2025 | -430,000.00 |
| Mar 31, 2025 | 10.84 Mn |
| Dec 31, 2024 | 21.46 Mn |
| Sep 30, 2024 | 6.55 Mn |
| Jun 30, 2024 | 8.09 Mn |
| Mar 31, 2024 | 10.32 Mn |
| Dec 31, 2023 | 11.10 Mn |
| Sep 30, 2023 | 13.49 Mn |
| Jun 30, 2023 | 13.13 Mn |
| Mar 31, 2023 | 11.71 Mn |
| Dec 31, 2022 | 8.84 Mn |
| Sep 30, 2022 | 8.79 Mn |
| Jun 30, 2022 | 9.06 Mn |
| Mar 31, 2022 | 8.51 Mn |
| Dec 31, 2021 | 6.26 Mn |
| Sep 30, 2021 | 8.61 Mn |